People channel feed

New­ly named Abeona chief Carsten Thiel boot­ed af­ter the board ac­cus­es him of mis­con­duct in­volv­ing col­leagues

7 years ago

Rolling up its sleeves, Ax­o­vant scoops up five gene ther­a­py vets to pro­pel new pipeline

7 years ago

Ju­ry finds for­mer Aveo CFO David John­ston li­able for scheme to mis­lead in­vestors

7 years ago

Is As­traZeneca look­ing for the ide­al can­di­date to re­place Pas­cal So­ri­ot?

7 years ago

Bil­lion­aire gifts Har­vard a his­toric $200M to 'ex­pe­dite' trans­la­tion­al bio­med­ical re­search work

7 years ago
Discovery

The res­ur­rec­tion of LUM001: Mike Grey gets his drug back from Shire — along with $120M to gam­ble on PhI­II tri­als

7 years ago
Startups

Fresh from a $72M raise, Jeff Aron­in's new lead rare dis­ease drug is flagged as a fail­ure

7 years ago
R&D

Rat­tled by set­backs, Cel­gene turns to ex-Mer­ck R&D star Alise Re­icin to re­pair its dam­aged de­vel­op­ment rep

7 years ago
R&D

Buy­out deal loom­ing, No­vo Nordisk raids As­traZeneca for a new chief to run its strug­gling bio­phar­ma busi­ness

7 years ago

Fol­low­ing the ex­o­dus at Im­muno­core, Eliot Forster takes the reins at F-star — how long be­fore the crossover and an IPO?

7 years ago

#BI­IS18 In­ter­view: Or­biMed Asi­a's Jonathan Wang on his up­bring­ing, de­cid­ing against a con­sult­ing ca­reer, blunt ad­vice for Chi­nese en­tre­pre­neurs, and more

7 years ago
China

Ex-Cel­gene deal­mak­er George Golumbes­ki joins up to guide Car­rick on its can­cer drug quest — and maybe an IPO as well

7 years ago

Walk­ing the walk, Al­ny­lam ap­points for­mer FDA head Mar­garet Ham­burg to the board

7 years ago

Ex­clu­sive: At Hal Bar­ron’s R&D group at GSK, con­sen­sus is out, lead­ers are in and watch out for an ‘in­tense dri­ve’ to spur the late-stage pipeline

7 years ago
R&D

New Pfiz­er CEO Al­bert Bourla shakes up the top team that will now lead the phar­ma gi­ant -- and there's a chief dig­i­tal of­fi­cer com­ing on board

7 years ago

Nim­bus chief Don Nichol­son hits the ex­it, hand­ing top job over to Jeb Keiper

7 years ago

Forty Sev­en adds No­bel win­ner Jim Al­li­son to a dream team of sci­en­tif­ic ad­vis­ers

7 years ago

Bellde­grun and Chang groom their biotech uni­corn Al­lo­gene for a mon­ster $288M — or so — IPO

7 years ago
Financing

Can­cer R&D stars Jim Al­li­son, Tasuku Hon­jo award­ed No­bel prize for im­munother­a­py dis­cov­er­ies

7 years ago

Ian Read taps his care­ful­ly groomed suc­ces­sor Al­bert Bourla as the next Pfiz­er CEO. What's his fu­ture look like?

7 years ago
Peer Review

A play­er in the bustling mi­cro­bio­me R&D are­na pro­motes its CSO to the top post -- just ahead of a PhII NASH study

7 years ago

Mer­ck board waves off a forced re­tire­ment for CEO Ken Fra­zier, hap­py to ex­tend his reign

7 years ago

As­traZeneca CEO Pas­cal So­ri­ot: 'I'm the low­est-paid CEO in the whole in­dus­try'

7 years ago

Fresh from the No­var­tis/Trump scan­dal, ex-CEO Joe Jimenez jumps on the board of uBio­me — a biotech launch­ing an R&D group

7 years ago
Financing
First page Previous page 83848586878889 Next page Last page
A service from the Financial Times